Changes in Thymus and Activation-Regulated Chemokine in Patients With Type 2 Inflammatory Disease Receiving Dupilumab

J Investig Allergol Clin Immunol. 2023 Feb 21;33(1):74-75. doi: 10.18176/jiaci.0874. Epub 2022 Dec 22.

Authors

B Zhou¹, S Liang¹, S Shang¹, L Xiang¹, L Li¹

Affiliation

¹ Department of Dermatology, Beijing Friendship Hospital, Capital Medical University, Beijing, China.

PMID: 36546446
DOI: 10.18176/jiaci.0874

No abstract available

Keywords: Atopic dermatitis; Dupilumab; Thymus and activation-regulated chemokine; Type 2 inflammatory disease.

Publication types

Letter

MeSH terms

Antibodies, Monoclonal, Humanized / therapeutic use
Chemokine CCL17*
Chemokines
Dermatitis, Atopic* / drug therapy
Humans
Severity of Illness Index
Treatment Outcome

Substances

dupilumab
Chemokine CCL17
Antibodies, Monoclonal, Humanized
Chemokines